Crine carcinoma Rhabdomyosarcoma Other Pre-operative T Dimethyl sulfone Epigenetic Reader Domain classification Tx T1 T2 T3 T4a T4b Pre-operative N classification N0 N1 N2b N2c Retropharyngeal Post-operative T classification T0 T1 T2 T3 T4a T4b First tumor Recurrence Pre-operative remedies (number and percentage) Chemotherapy Radiochemotherapy Surgical technique (quantity and percentage) Craniofacial resection Endoscopic trans-nasal resection Cranio-endoscopic resection 176 57 (169) three.eight (139/37) two (1 ) 89 (51 ) 85 (48 ) 155 (88 ) 13 (7 ) three (two ) 1 1 1 1 1 72 (41 ) 36 (20 ) 28 (16 ) ten (six ) 9 (5 ) six (three ) three (two ) 12 eight (five ) 3 (two ) 36 (20 ) 47 (27 ) 23 (14 ) 58 (33 ) 168 (95 ) 13 (2 ) 3 (two ) 1 11 (six ) 5 (three ) 65 (37 ) 23 (13 ) 16 (9 ) 56 (32 ) 169 (96 ) 7 (four ) 66 (38 ) 1 58 (33 ) 117 (66 )Cancers 2021, 13,7 ofTable 2. Cont. Patients (Quantity) Post-operative therapies (quantity and percentage) Exclusive radiotherapy Radiochemotherapy Histological invasion: Bony skull base Dura Olfactory bulbs Cerebral parenchyma Bony orbital walls Orbital content149 (85 ) 10 (six ) 78 (44 ) 46 (26 ) 25 (14 ) 9 (5 ) 36 (20 ) 15 (9 )3.three. Radiohistological Correlation The diagnostic performances of CT and MRI for the diagnosis of skull base/orbital invasion are summarized in Tables three and four.Table three. Radiohistological correlation. Anatomical Structure Bony skull base Imaging Radiological Sign Make contact with with out bony modification Minor erosion Big erosion Minor modification Important modification two mm Linear enhancement 2 mm 2 mm Nodular two mm enhancement Smooth Deformation Irregular 45 Speak to angle 45 Edema Tumoral invasion Get in touch with with out bony modification Minor erosion Significant erosion Minor modification Main modification Invasion with the fat between tumor and oculomotor muscle Smooth Deformation Irregular 45 Get in touch with angle 45 Invasion of oculomotor muscle Number of Abnormalities 41 32 54 40 45 39 14 5 23 41 15 35 21 four 1 47 22 43 21 40 24 45 six 40 11 3 PPV (CI95) 7.3 (1.59.9) 50.0 (32.77.three) 77.8 (66.78.9) 45.0 (29.60.4) 88.9 (79.78.1) 38.five (23.23.7) 71.4 (41,91.6) 40.0 (5.35.3) 87.0 (66.47.2) 46.3 (31.11.six) 86.7 (59.58.three) 37.1 (21.13.2) 85.7 (63.77.0) 50.0 (six.83.two) one hundred (2.500) 0 (0.6) 27.3 (10.70.two) 48.eight (33.93.eight) 28.6 (11.32.2) 47.5 (32.03.0) 33.three (15.65.3) 28.6 (13.63.5) 33.3 (4.37.7) 21.2 (7.35.two) 45.five (16.86.6) 33.3 (0.80.six) KappaCT scanner MRI0.87 0.85 0.78 0.79 0.73 0.84 0.52 0.85 0.90 0.91 0.75 0.80DuraMRICerebral parenchyma Orbital bony wallsMRI CT scanner MRIOrbital contentMRIMinor erosion/modification: 2 mm; key erosion/modification: 2 mm.Table four. Radiological conclusion. Radiological Heneicosanoic acid Metabolic Enzyme/Protease conclusion True positives Accurate negatives False positives False negatives Bony Skull Base 60 82 16 18 Dura 33 97 21 9 Cerebral Parenchyma 1 151 1 7 Orbital Bony Walls 29 113 27 7 Orbital Content 4 142 4Cancers 2021, 13,8 ofTable 4. Cont. Radiological Conclusion Sensitivity (CI95) Specificity (CI95) PPV (CI95) NPV (CI95) Accuracy (CI95) Kappa Yule’s Q Bony Skull Base 76.9 (67.66.3) 83.7 (76.41.0) 79.0 (69.88.1) 82.0 (74.59.five) 80.7 (74.96.5) 0.87 0.61 Dura 78.six (66.21.0) 82.two (75.39.1) 61.1 (48.14.1) 91.five (86.26.eight) 81.3 (75.27,3) 0.96 0.89 Cerebral Parenchyma 12.five (0.32.7) 99.three (98.one hundred) 50.0 (1.38.7) 95.6 (92.48.8) 95.0 (91.68.four) 0.49 0.91 Orbital Bony Walls 80.six (67.63.5) 80.7 (74.27.3) 51.eight (38.74.9) 94,two (90.08.four) 76.3 (70.22.5) 0.93 0.61 Orbital Content 28.6 (8.48.1) 97.3 (94.69.9) 50.0 (15.44.7) 93.4 (89.57.4) 91.three (86.95.6) 0.41 0.For the dura, cerebral parenchyma and orbital.
